Skip to main content
. 2020 Jun 30;10:913. doi: 10.3389/fonc.2020.00913

Figure 3.

Figure 3

Survival curves under biomarker-defined subgroups. Kaplan–Meier survival curves of progression-free survival (PFS; A) and overall survival (OS; C) of nivolumab-treated patients were stratified by the platelet-to-lymphocyte ratio (PLR) before ICI treatment. PFS (B) and OS (D) of nivolumab-treated patients were stratified by albumin before treatment. OS (E) of nivolumab-treated patients was stratified by PLR before the fifth dose.